News about Integra

Integra (IART) reported Q3 revenue of $411.2 million, up 2.5% organically despite a $7 million hit from flooding at its Cincinnati facility, with adjusted EPS of $0.59 versus $0.54 a year earlier. Specialty Surgery revenue rose 4.2% to $304.1 million, led by neurosurgery (up 6.5%) and international markets (up 7.8%), while Tissue Reconstruction fell 2.2% to $107.1 million on competitive pressure in its urinary bladder matrix (UBM) portfolio. Management expects a further $15–20 million revenue reduction in Q4 and lowered full-year 2026 revenue guidance to $1.634–1.654 billion, with adjusted EPS guidance of $2.30–2.40. The $2.1 billion debt refinancing completed October 19, 2026 is expected to add about $8 million in interest expense in Q4 and $24 million in 2027, though net debt remained $1.5 billion with a 3.8x leverage ratio.